Amyris & CJ CheilJedang Corporation Creating Manufacturing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Amyris & CJ CheilJedang Corporation Creating Manufacturing and Sales Partnership

EMERYVILLE, Calif., May 20, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq: AMRS ), the industrial bioscience company, and South Korea-based CJ CheilJedang Corporation (“CJ”)(KRX:097950), today announced that the companies have signed a Memorandum of Understanding (MOU) to support large-scale manufacturing of Amyris’s farnesene in existing CJ facilities. The arrangement described in the MOU would enable Amyris to utilize CJ’s state of the art manufacturing capacity while minimizing the capital investment necessary to support projected near- and mid-term demand for product applications using farnesene. The partnership is also expected to include the opportunity for CJ Bio (division of CJ CheilJedang) to market select Amyris products in Asian markets as well as the potential for Amyris to develop several products for CJ Bio. The companies are targeting completing a definitive agreement by the first week of August 2016.

“We are very pleased with the innovative approach of CJ CheilJedang, to support quickly ramping up our farnesene capacity with minimal capital investment and with the collaborative partnership to market some of our products in Asia,” said John Melo, President & CEO of Amyris. “This partnership completes our commercialization strategy by providing us the ability to meet our farnesene demand from our current partners without new investment from Amyris and underpins our expected capacity needs to meet farnesene demand that would require building 3-4 new plants the size of our Brotas facility by 2020. We are also pleased with the opportunity to partner with CJ for sales efforts in Asia and the potential to collaborate on new products that meet the needs of their existing customers.”

“We are excited to partner with Amyris and leverage the world’s leading Industrial Biotechnologies to support the growing bio economy in Asia,” said Hang Duk Roh, Head of CJ CheilJedang BIO.

About CJ CheilJedang Corporation    CJ CheilJedang, is a Korean-based food, feed, and bioscience company, and a subsidiary of the CJ Group. CJ CheilJedang is a global leader in the area of industrial biotechnology with innovations in fermentation and purification technologies. CJ is a leading producer of fermentation-based products such as feed amino acids, MSG, and nucleotides with global manufacturing and business operations in 6 continents. As a socially responsible company, CJ strives toward practicing carbon-neutral manufacturing operations by utilizing renewable raw materials and developing value-added co-products to minimize waste into the environment.

CJ Bio is a division of CJ CheilJedang and operates world-scale fermentation facilities in the United States, China, Indonesia, Malaysia and Brazil.

About Amyris

Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com .

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as expectations regarding the company’s ability to establish a definitive agreement following execution of the non-binding MOU with CJ, future demand for Amyris products, successful scale-up of manufacturing at CJ facilities and the potential for the two companies to engage in joint product sales and new product development) that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including, among other things, risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-Q filed on May 10, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris is a registered trademark of Amyris, Inc. All other trademarks are the property of their respective owners.

Contact: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 investor@amyris.com pr@amyris.com                                                                                

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 342

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 73

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 103

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 423

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 562

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 344

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 585

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 129

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

Investment Growth: What $100 in UBS Stock Means Today

Updated Category News Views 106

Understanding UBS Group AG's Stock Performance UBS Group AG (NYSE: UBS) has shown significant resilience and growth in the stock market over the past five years. The company has outperformed the overall market by an impressive 9.96%, yielding an average annual return of 24.36%. This substantial performance highlights UBS's strength in a competitive landscape, positioning...

Continue Reading
Perella Weinberg's Financial Results Showcase Strategic Moves

Updated Category News Views 208

Overview of Financial Performance Recently, Perella Weinberg Partners (NASDAQ: PWP) shared its financial results for the third quarter, showcasing a nuanced landscape of both challenges and opportunities. The firm reported revenues totaling $165 million during the quarter, reflecting a 41% decline from the same period a year prior, when it achieved record revenues of $278...

Continue Reading
Kensington Vanguard Welcomes New Leaders in Phoenix Office

Updated Category News Views 625

Kensington Vanguard Expands Leadership Team in Phoenix Kensington Vanguard National Land Services (KV), a well-regarded title insurance agency, is thrilled to announce new additions to its Phoenix office. Distinguished professionals Chadwick Campbell and Scott Schmidt have joined KV, enhancing the company's drive for service excellence in the region. Introducing Chadwick...

Continue Reading
Investor Alert: Funko, Inc. Faces Investigation Over Stock Decline

Updated Category News Views 238

Investor Alert: Funko, Inc. Faces Investigation Over Stock Decline FUNKO, INC. (NASDAQ: FNKO) is currently at the center of an investigation concerning potential securities fraud. Pomerantz LLP, a firm known for its expertise in corporate and securities law, is investigating claims on behalf of investors who are concerned about recent developments involving the company....

Continue Reading
CVB Financial Corp. Continues Tradition of Quarterly Dividends

Updated Category News Views 187

CVB Financial Corp. Continues Tradition of Quarterly Dividends CVB Financial Corp. (NASDAQ: CVBF) recently declared an impressive cash dividend of twenty cents ($0.20) per share for the first quarter. This announcement represents the company's 142nd consecutive quarterly dividend, highlighting a consistent commitment to rewarding investors. The decision was made during a...

Continue Reading